Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5034-5042

  Rosenzweig, Jason A ^a   Brackman, Sheri M ^b   Kirtley, Michelle L ^b   Sha, Jian ^b   Erova, Tatiana E ^b   Yeager, Linsey A ^b,c   Peterson, Johnny W ^b,c   Xu, Ze Qi ^d   Chopra, Ashok K ^b,c  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d Advanced Life Sciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETHROMYCIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); LEVOFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BLOOD; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; NONHUMAN; PLAGUE; PRIORITY JOURNAL; RAT; SPLEEN; YERSINIA PESTIS;

ANIMALS; ANTI-BACTERIAL AGENTS; FEMALE; KETOLIDES; OFLOXACIN; PLAGUE; RATS; YERSINIA PESTIS;

EID: 80054683746     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00632-11     Document Type: Article

References (33)

1. Agar, S. L., et al. 2009. Characterization of the rat pneumonic plague model: infection kinetics following aerosolization of Yersinia pestis CO92. Microbes Infect. 11:205-214.
2. Alibek, K., and S. Handelman. 1999. Biohazard: the chilling true story of the largest covert biological weapons program in the world - told from inside by the man who ran it. Random House Inc., New York, NY.
3. Alvarez, M. L., and G. A. Cardineau. 2010. Prevention of bubonic and pneumonic plague using plant-derived vaccines. Biotechnol. Adv. 28:184-196.
4. Chen, T. H., L. E. Foster, and K. F. Meyer. 1974. Comparison of the immune response to three different Yersinia pestis vaccines in guinea pigs and langurs. J. Infect. Dis. 129(Suppl.):S53-S61.
5. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-8th edition. M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Cully, J. F., and E. S. Williams. 2001. Interspecific comparisons of sylvatic plague in prairie dogs. J. Mammal. 82:894-905. (Pubitemid 33146155)
7. Evans, R. G., J. M. Crutcher, B. Shadel, B. Clements, and M. S. Bronze. 2002. Terrorism from a public health perspective. Am. J. Med. Sci. 323:291-298. (Pubitemid 34657231)
8. Galimand, M., et al. 1997. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N. Engl. J. Med. 337:677-680. (Pubitemid 27375474)
9. Greenfield, R. A., et al. 2002. Bacterial pathogens as biological weapons and agents of bioterrorism. Am. J. Med. Sci. 323:299-315. (Pubitemid 34651568)
10. Guiyoule, A., et al. 2001. Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. Emerg. Infect. Dis. 7:43-48. (Pubitemid 32173332)
11. Heine, H. S., et al. 2007. Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. J. Infect. Dis. 196:782-787. (Pubitemid 47293862)
12. Heine, H. S., et al. 2006. 46th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 27 to 30 September 2006, poster E-1853.
13. Heymann, D. L. 2005. Emerging and re-emerging infectious diseases from plague and cholera to Ebola and AIDS: a potential for international spread that transcends the defenses of any single country. J. Contig. Crisis Manag. 13:29-31.
14. Inglesby, T. V., et al. 2000. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 283: 2281-2290. (Pubitemid 30246781)
15. Jawetz, E., and K. F. Meyer. 1944. The behavior of virulent and avirulent P. pestis in normal and immune experimental animals. J. Infect. Dis. 74:1-13.
16. Kim, M. K., et al. 2002. Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. Antimicrob. Agents Chemother. 46:3185-3192.
17. Koster, F., et al. 2010. Milestones in progression of primary pneumonic plague in cynomolgus macaques. Infect. Immun. 78:2946-2955.
18. Ligon, B. L. 2006. Plague: a review of its history and potential as a biological weapon. Semin. Pediatr. Infect. Dis. 17:161-170. (Pubitemid 44278622)
19. Louie, A., M. R. Deziel, W. Liu, and G. L. Drusano. 2007. Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy. Antimicrob. Agents Chemother. 51:2661-2667. (Pubitemid 47206197)
20. Louie, A., et al. 2011. Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance. Antimicrob. Agents Chemother. 55:822-830.
21. Louie, A., et al. 2011. Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 55:2623-2628.
22. Luzzaro, F. 2008. Fluoroquinolones and Gram-negative bacteria: antimicrobial activity and mechanisms of resistance. Infez. Med. 16(Suppl. 2):5-11. (In Italian.)
23. Mima, T., H. P. Schweizer, and Z. Q. Xu. 2011. In vitro activity of cethromycin against Burkholderia pseudomallei and investigation of mechanism of resistance. J. Antimicrob. Chemother. 66:73-78.
24. Perry, R. D., and J. D. Fetherston. 1997. Yersinia pestis-etiologic agent of plague. Clin. Microbiol. Rev. 10:35-66.
25. Peterson, J. W., et al. 2010. Protection afforded by fluoroquinolones in animal models of respiratory infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis. Open Microbiol. J. 4:34-46.
26. Rafie, S., C. MacDougall, and C. L. James. 2010. Cethromycin: a promising new ketolide antibiotic for respiratory infections. Pharmacotherapy 30:290-303.
27. Rios, A. M., et al. 2004. Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection. Antimicrob. Agents Chemother. 48:2897-2904. (Pubitemid 38989153)
28. Rosenzweig, J. A., et al. 2011. Progress on plague vaccine development. Appl. Microbiol. Biotechnol. 91:265-286.
29. Sebbane, F., D. Gardner, D. Long, B. B. Gowen, and B. J. Hinnebusch. 2005. Kinetics of disease progression and host response in a rat model of bubonic plague. Am. J. Pathol. 166:1427-1439. (Pubitemid 40586513)
30. Sha, J., et al. 2008. Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague. Infect. Immun. 76:1390-1409. (Pubitemid 351561984)
31. Sha, J., et al. 2011. Characterization of an F1 deletion mutant of Yersinia pestis CO92, pathogenic role of F1 antigen in bubonic and pneumonic plague, and evaluation of sensitivity and specificity of F1 antigen capturebased dipsticks. J. Clin. Microbiol. 49:1708-1715.
32. Sha, J., et al. 2005. The type III secretion system and cytotoxic enterotoxin alter the virulence of Aeromonas hydrophila. Infect. Immun. 73:6446-6457. (Pubitemid 41368806)
33. Wayson, N. E., M. C. McMahon, and F. M. Prince. 1946. An evaluation of three plague vaccines against infection in guinea pigs induced by natural and artificial methods. Public Health Rep. 61:1511-1518.